Home
PBM
PBM News

Latest PSYENCE BIOMEDICAL LTD (PBM) News on June 8, 2025

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Newsfile

12 days ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Newsfile

a month ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Newsfile

2 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Group Announces Share Consolidation

GlobeNewswire

2 months ago

Psyence Group Announces Share Consolidation

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Newsfile

2 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Newsfile

2 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Newsfile

2 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

GlobeNewswire

2 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Newsfile

3 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

GlobeNewswire

3 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

GlobeNewswire

3 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Announces Closing of $2.0 Million Private Placement

GlobeNewswire

5 months ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

TipRanks

5 months ago

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

Psyence Biomed Announces $2.0 Million Private Placement

GlobeNewswire

6 months ago

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

GlobeNewswire

6 months ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

GlobeNewswire

6 months ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical executes binding agreements with Optimi Health

TipRanks

6 months ago

Psyence Biomedical executes binding agreements with Optimi Health

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

GlobeNewswire

6 months ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

GlobeNewswire

6 months ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

GlobeNewswire

6 months ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Market Exclusive

6 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

GlobeNewswire

7 months ago

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

GlobeNewswire

7 months ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

GlobeNewswire

7 months ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

GlobeNewswire

7 months ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

GlobeNewswire

7 months ago

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

7 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire

7 months ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

GlobeNewswire

8 months ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

GlobeNewswire

8 months ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

GlobeNewswire

8 months ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

GlobeNewswire

9 months ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

GlobeNewswire

9 months ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

9 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

9 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire

9 months ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

GlobeNewswire

9 months ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire

9 months ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

GlobeNewswire

9 months ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

GlobeNewswire

9 months ago

Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

GlobeNewswire

9 months ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

GlobeNewswire

9 months ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

GlobeNewswire

10 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Newsfile

10 months ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

GlobeNewswire

10 months ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

10 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire

10 months ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

US home sales dip, Secret Service director resigns: Catalysts

Yahoo Finance Video

a year ago

US home sales dip, Secret Service director resigns: Catalysts

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire

a year ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

GlobeNewswire

a year ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

GlobeNewswire

a year ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

a year ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire

a year ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

GlobeNewswire

a year ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

GlobeNewswire

a year ago

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

GlobeNewswire

a year ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

a year ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

GlobeNewswire

a year ago

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

GlobeNewswire

a year ago

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

GlobeNewswire

a year ago

Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

Yahoo Finance

a year ago

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

Girona take Liga lead back with win at Celta

AFP

a year ago

Girona take Liga lead back with win at Celta

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

Motley Fool

a year ago

20 "Tech" Stocks Make Up Over 35% of the S&P 500. Here's What That Means for Your Portfolio.

Whether or not the Fed cuts rates is not the right question

Yahoo Finance

a year ago

Whether or not the Fed cuts rates is not the right question

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

Motley Fool

a year ago

Bitcoin ETFs Are Here. Why You Should Buy and Hold Long Term

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

Motley Fool

a year ago

The S&P 500 Just Hit an All-Time High. Here's 1 Artificial Intelligence (AI) Stock to Buy and Hold Hand Over Fist.

Springfield News-Sun, Ohio

a year ago

Local region economic outlook is strong for 2024

Dynagas LNG Partners LP Declares Cash Distribution on Its Series A Preferred units

GlobeNewswire

a year ago

Dynagas LNG Partners LP Declares Cash Distribution on Its Series A Preferred units

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

GlobeNewswire

a year ago

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

GlobeNewswire

a year ago

QuantaSing Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

Vroom Announces "At The Market" (ATM) Equity Offering Program

Business Wire

2 years ago

Vroom Announces "At The Market" (ATM) Equity Offering Program

AVITA Medical Updates Full Year 2023 Guidance

GlobeNewswire

2 years ago

AVITA Medical Updates Full Year 2023 Guidance

Skillsoft Research Reveals Organizations Struggling to Balance CSR Core Values With External Pressures

Business Wire

2 years ago

Skillsoft Research Reveals Organizations Struggling to Balance CSR Core Values With External Pressures

Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2024

PR Newswire

2 years ago

Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2024

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Xtant Medical Holdings Inc Earnings Call

Xtant Medical to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Xtant Medical to Participate in Upcoming Investor Conferences

Innovative Food Holdings, Inc. Reports Financial Results for Third Quarter of 2023

GlobeNewswire

2 years ago

Innovative Food Holdings, Inc. Reports Financial Results for Third Quarter of 2023

Share on Social Networks: